肾康注射液联合前列地尔对早期糖尿病肾病患者尿蛋白的影响

Effect on proteinuria in the early diabetic nephropathy case with prostaglandin E_1 and Shenkang injection

目的:观察短期静脉应用前列地尔(LipoPG1E)联合肾康注射液对早期糖尿病肾病患者肾功能及尿蛋白的影响。方法:早期糖尿病肾病患者74例,年龄38～72岁;男40例,女34例。分为对照组12例、前列地尔组16例、肾康注射液组18例、前列地尔联合肾康注射液组28例。前列地尔组静脉推注前列地尔(凯时)10μg,qd,连续14d;肾康注射液组静脉滴注肾康注射液100mL(加入5?葡萄糖注射液250mL),qd,连续14d;联合组静脉给予前列地尔(凯时)10μg及肾康注射液100mL,qd,连续14d。对照组不给上述治疗措施。控制血糖、血压、血脂等其他治疗方法各组相同。结果:和对照组比较,凯时组、肾康注射液组及联合组患者尿总蛋白和微量白蛋白明显降低(P<0.01),其中肾康注射液组及联合组患者血尿素氮(BUN)、肌酐(SCr)亦明显降低(P<0.01)。组间比较,凯时组与肾康注射液组患者尿总蛋白和微量白蛋白降低差异无显著性(P>0.05),联合组患者尿总蛋白、微量白蛋白、血肌酐及尿素氮较凯时组和肾康注射液均明显降低(P<0.01)。结论:前列地尔与肾康注射液短期静脉应用均能明显降低早期糖尿病肾病患者尿蛋白,但二者联合应用疗效更显著。

OBJECTIVE To observe the effect on proteinuria in the early diabetic nephropathy case with prostaglandin E1 and Shenkang injection. METHODS 44 patients with early diabetic nephropathy were divided randomly into four groups. 11 patients were treated with 10 g Lipo PGE1 daily for 14 days. 11 patients were treated with 100 mL Shenkang injection daily for 14 days. 13 patients were treated with 10 g Lipo PGE1 and 100 mL Shenkang injection daily for 14 days： 9 patients in control group. RESULTS In treating group （Lipo PGE1 group, Shenkang injection group and the combination treatment group）, proteinuria and albuminuria were significantly reduced as compared with the control group （P〈0. 05）. Among them , blood BUN, SCr in the Shenkang injection group and combination treatment group were also declined （P〈0. 05）. Compared with groups, Proteinuria, albuminuria and blood BUN SCr of the combination treatment group were decreased more than the Lipo PGE1 and Shenkang injection group （P〈0. 01）. CONCLUSION Both prostaglandin E1 and Shenkang injection may decrease proteinuria for early diabetic nephropathy, but combination treatment may be better.